Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
Cholinesterase inhibitors (ChEIs) are the first line pharmacotherapy for the symptoms of Alzheimer’s disease (AD). Though ChEIs offer modest cognitive benefits in early AD, literature addressing their continued use in severe AD is scarce. This study assessed the safety of discontinuing ChEIs in ins...
Main Author: | |
---|---|
Other Authors: | |
Language: | en_ca |
Published: |
2014
|
Subjects: | |
Online Access: | http://hdl.handle.net/1807/44051 |